Workflow
华恒生物(688639) - 2023 Q3 - 季度财报
AHBAHB(SH:688639)2023-10-25 16:00

Financial Performance - The company's revenue for Q3 2023 reached ¥514,272,654.57, representing a year-on-year increase of 44.92%[4] - Net profit attributable to shareholders for Q3 2023 was ¥128,712,551.61, up 46.19% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥125,519,890.78, reflecting a 54.86% increase year-on-year[4] - Basic earnings per share for Q3 2023 were ¥0.82, a 46.43% increase from the same period last year[5] - The company reported a total net profit of ¥319,949,196.04 for the year-to-date, reflecting a 47.42% increase compared to the same period last year[4] - Net profit for Q3 2023 was ¥319,399,135.43, compared to ¥216,987,363.31 in Q3 2022, indicating a year-over-year increase of about 47.2%[17] - The total comprehensive income for Q3 2023 was ¥319,399,135.43, compared to ¥216,987,363.31 in Q3 2022, indicating a year-over-year increase of approximately 47.2%[18] Cash Flow - The net cash flow from operating activities for Q3 2023 was ¥110,472,737.89, an increase of 35.22% compared to the previous year[5] - In Q3 2023, the cash inflow from operating activities amounted to CNY 1,395,423,545.57, compared to CNY 923,826,718.14 in the same period last year, representing an increase of approximately 51.1%[20] - The net cash flow from operating activities for Q3 2023 was CNY 369,988,573.38, up from CNY 247,467,316.52 year-on-year, indicating a growth of about 49.5%[20] - The cash outflow for purchasing goods and services was CNY 754,034,733.68, which is an increase from CNY 509,993,877.39 in the previous year, reflecting a rise of approximately 47.8%[20] - The net cash flow from investing activities was negative at CNY -774,817,204.53, compared to a positive cash flow of CNY 681,851.84 in the same quarter last year[21] - Cash inflow from financing activities totaled CNY 650,026,302.53, a significant increase from CNY 56,219,185.10 in the previous year[21] - The net cash flow from financing activities for Q3 2023 was CNY 432,985,012.36, compared to a negative cash flow of CNY -22,493,410.71 in the same period last year[21] Assets and Liabilities - Total assets at the end of Q3 2023 amounted to ¥2,809,488,085.74, marking a 38.60% increase from the end of the previous year[5] - Current assets amounted to CNY 752,938,520.16, down from CNY 863,055,449.61, indicating a decrease of about 12.8%[13] - Cash and cash equivalents increased to CNY 181,608,810.44 from CNY 147,463,603.30, representing a growth of approximately 23.2%[12] - Accounts receivable decreased to CNY 199,133,714.67 from CNY 260,385,875.17, showing a decline of about 23.5%[13] - Inventory rose to CNY 168,453,883.15 from CNY 135,513,945.72, marking an increase of approximately 24.3%[13] - Non-current assets totaled CNY 2,056,549,565.58, up from CNY 1,164,030,348.23, reflecting a significant increase of about 76.7%[13] - The total liabilities as of Q3 2023 amounted to ¥1,108,106,191.33, up from ¥545,440,388.40 in the previous year, reflecting an increase of approximately 102.9%[15] - The company's total equity attributable to shareholders reached ¥1,700,780,695.11, compared to ¥1,480,494,149.53 in the same quarter last year, marking an increase of about 14.8%[15] - The total current liabilities as of Q3 2023 were ¥794,776,651.78, compared to ¥388,754,368.98 in the previous year, indicating an increase of approximately 104.0%[15] - The company's total non-current liabilities reached ¥313,329,539.55, up from ¥156,686,019.42 in the previous year, representing an increase of about 100.0%[15] Research and Development - The company's R&D investment for Q3 2023 totaled ¥22,962,262.57, a decrease of 9.34% year-on-year[5] - The R&D investment as a percentage of revenue was 4.46%, down 2.68 percentage points compared to the same period last year[5] - Research and development expenses for the first three quarters of 2023 were ¥77,313,400.23, up from ¥58,698,127.08 in the same period of 2022, representing a growth of approximately 31.6%[16] Shareholder Information - The company reported a total of 10 major shareholders, with the largest being Guo Henghua, holding 31,191,231 shares[9] Market and Product Development - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[10] - There are no significant changes in the company's financing or refinancing activities reported for this quarter[10]